To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Mylan Launches Generic Yasmin® Tablets
Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent pregnancy.
Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.03 mg, had U.S. sales of approximately $137.6 million for the 12 months ending June 30, 2015, according to IMS Health. The immediate availability of this product represents Mylan's thirteenth oral contraceptive launch in the U.S.
Currently, Mylan has 266 ANDAs pending FDA approval representing $99.5 billion in annual brand sales, according to IMS Health. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $33.4 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
